Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study

Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients. A single-institute retrospective cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Keiji, Kogure, Yoshihito, Torii, Atsushi, Shiraishi, Kazuhiro, Yamada, Arisa, Ishida, Akane, Shigematsu, Fumie, Nozawa, Kazuki, Niwa, Hideyuki, Oka, Saori, Nakahata, Masashi, Kitagawa, Chiyoe, Oki, Masahide, Saka, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831182/
https://www.ncbi.nlm.nih.gov/pubmed/30817634
http://dx.doi.org/10.1097/MD.0000000000014758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831182/
https://www.ncbi.nlm.nih.gov/pubmed/30817634
http://dx.doi.org/10.1097/MD.0000000000014758

Ejemplares similares